Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936101 · ClinicalTrials.gov registry record
Prenatal Genetic Diagnosis by Genomic Sequencing
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 1,097
- Enrollment target
NCT03936101: Completed study, sponsored by Columbia University.
NCT03936101 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 1,097 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03936101 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 1,097 participants
- Enrollment target
Study Summary
This study is evaluating the impact of prenatal sequencing on the management of fetuses with ultrasound abnormalities. The hypothesis is that a significant subset of fetal abnormalities have a genetic cause that can be identified by sequencing and that prenatal knowledge of this information will improve prenatal care, reduce unnecessary diagnostic testing, reduce the cost of care, and improve the quality of life for both the child and the family.
Primary Outcome
Reportable variants: defined as either Pathogenic / Likely pathogenic (P/LP) or variant of uncertain significance (VUS) identified by sequencing and deemed reportable by the Variant Adjudication Committee.
Interventions
- DIAGNOSTIC_TEST Prenatal Genomic Sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,097 participants |
| Start Date | 2019-06-28 |
| Est. Completion | 2024-03-25 |
What the finished NCT03936101 record still lists
NCT03936101 is an observational study that tracks outcomes without assigning an intervention. Its 1,097 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Prenatal Genomic Sequencing is the first listed.
NCT03936101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03936101 about?
NCT03936101 is a clinical study titled "Prenatal Genetic Diagnosis by Genomic Sequencing". This study is evaluating the impact of prenatal sequencing on the management of fetuses with ultrasound abnormalities. The hypothesis is that a significant subset of fetal abnormalities have a genetic cause that can be identified by sequencing and that prenatal knowledge of this information will imp...
What is the current status of trial NCT03936101?
This trial is currently completed. The enrollment target is 1,097 participants. The study started on 2019-06-28. Estimated completion is 2024-03-25.
What interventions are being tested in trial NCT03936101?
The interventions under investigation include: Prenatal Genomic Sequencing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03936101?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191744 · 1,095 participants · Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI